Printer Friendly

Sagent Pharmaceuticals gets FDA nod for injectable Orphenadrine Citrate.

M2 PHARMA-September 1, 2011-Sagent Pharmaceuticals gets FDA nod for injectable Orphenadrine Citrate(C)2011 M2 COMMUNICATIONS

1 September 2011 - US Sagent Pharmaceuticals Inc (NASDAQ:SGNT) said on Wednesday that the US Food and Drug Administration (FDA) has given the green light to the company's Orphenadrine Citrate Injection, USP, a skeletal muscle relaxant.

The company is to roll out the product in the third quarter of 2011. It will be sold in 60mg per 2 mL single-dose, latex-free vials.

Sagent said that the injectable Orphenadrine Citrate will include its PreventIV Measures packaging and labeling designed to help prevent medication errors.

IMS estimates that the US market for injectable orphenadrine in 2011 will reach USD4.3m (EUR3m).

(USD1 = EUR0.701)

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 1, 2011
Previous Article:Stryker to acquire Concentric Medical for USD135m.
Next Article:XOMA appoints interim CEO.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters